Updates on Bintrafusp alfa/M7824 Clinical Data

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Laureen Ojalvo, EMD Serono provides an overview of the moleculte Bintrafusp alfa/M7824. This molecule is an innovative, first-in-class bifunctional fusion protein composed of an anti-PD-L1 mAb fused with 2 extracellular domains of TGF-βRII (a TGF-β “trap”). The mechanism of action, pre-clinical and phase 1 studies of this molecule is discussed as well as an overview of the next wave of clinical development.

To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com